Citizens Jmp Has Lowered Expectations for Axon Enterprise (NASDAQ:AXON) Stock Price

Key Points

• Citizens Jmp lowered its price target on Axon from $825 to $700 while keeping a "market outperform" rating, amid several analyst target cuts but a consensus target of about $722.38 and mostly Buy ratings.
• Axon beat Q1 revenue expectations (around $800M) and cited explosive AI adoption—management raised full‑year revenue growth guidance to 30–32% and said AI product revenue surged roughly 700%, supporting optimism on recurring, higher‑margin software.
• The stock jumped about 9.4% intraday to $421.99, but carries a rich valuation (PE ~278x); insiders sold modestly and institutional investors own roughly 79% of the shares.

Axon Enterprise (NASDAQ:AXON - Get Free Report) had its price target lowered by Citizens Jmp from $825.00 to $700.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a "market outperform" rating on the biotechnology company's stock. Citizens Jmp's target price would suggest a potential upside of 65.88% from the company's previous close.

AXON has been the topic of a number of other reports. TD Cowen cut their price target on shares of Axon Enterprise from $950.00 to $825.00 and set a "buy" rating on the stock in a report on Wednesday, April 8th. UBS Group set a $440.00 price target on shares of Axon Enterprise in a report on Thursday. Royal Bank Of Canada cut their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an "outperform" rating on the stock in a report on Wednesday, February 25th. Morgan Stanley set a $600.00 price target on shares of Axon Enterprise in a report on Thursday. Finally, Piper Sandler cut their price target on shares of Axon Enterprise from $690.00 to $674.00 and set an "overweight" rating on the stock in a report on Thursday. Sixteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $722.38.

Axon Enterprise Stock Up 9.4%

AXON traded up $36.13 during mid-day trading on Thursday, reaching $421.99. 1,579,299 shares of the stock were exchanged, compared to its average volume of 1,049,641. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. The stock has a market capitalization of $34.00 billion, a PE ratio of 278.40, a price-to-earnings-growth ratio of 8.12 and a beta of 1.44. The company has a 50 day moving average price of $452.24 and a two-hundred day moving average price of $529.24. Axon Enterprise has a 1 year low of $339.01 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.55. The firm had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business's revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.08 EPS. As a group, research analysts anticipate that Axon Enterprise will post 1.41 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total value of $5,002,400.00. Following the sale, the chief executive officer directly owned 3,090,997 shares in the company, valued at approximately $1,546,240,339.28. The trade was a 0.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jeri Williams sold 157 shares of the business's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total value of $76,930.00. Following the completion of the sale, the director owned 1,159 shares in the company, valued at $567,910. This represents a 11.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,855 shares of company stock worth $7,109,828 in the last ninety days. 4.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently modified their holdings of AXON. Baillie Gifford & Co. increased its position in shares of Axon Enterprise by 1,198.7% during the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company's stock valued at $932,869,000 after buying an additional 1,516,099 shares during the period. Edgewood Management LLC bought a new stake in shares of Axon Enterprise during the fourth quarter valued at about $846,516,000. Wellington Management Group LLP increased its position in shares of Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company's stock valued at $874,463,000 after buying an additional 1,179,038 shares during the period. Norges Bank bought a new stake in shares of Axon Enterprise during the fourth quarter valued at about $515,764,000. Finally, Vanguard Group Inc. increased its position in shares of Axon Enterprise by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock valued at $6,684,217,000 after buying an additional 376,904 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q1 revenue beat and strong top-line growth — Axon reported $807M in Q1 revenue (up ~34% YoY), with software & services up 35% and management raised full‑year revenue growth to 30–32% while reaffirming margins and strong cash‑flow targets. Axon reports Q1 2026 revenue of $807 million
• Positive Sentiment: Explosive AI product adoption — management said AI product revenue was up ~700% and counter‑drone revenue rose >300%, driving the guidance raise and investor enthusiasm about recurring ARR and higher‑margin software. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Analysts reiterate conviction — multiple firms (William Blair, Needham) maintained Buy ratings and bullish targets (Needham $600 PT), supporting upside expectations. Axon Earns Buy Rating on Robust ARR Growth Axon Maintained at Buy as Strong Growth Outlook Supports Unchanged $600 Price Target
• Neutral Sentiment: Investor resources — transcripts, estimate comparisons and previews are circulating to guide thesis and model updates ahead of analyst revisions. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Mixed earnings signals — while revenue beat, non‑GAAP EPS was marginally mixed versus some estimates (tiny beat vs some consensus, small miss vs others), which capped upside for some traders. Compared to Estimates, Axon Q1 Earnings
• Negative Sentiment: Analyst target tweak & valuation pressure — Piper Sandler trimmed its price target slightly (still Overweight), and recent YTD share weakness / high P/E leave sensitivity to execution and multiple compression. Piper Sandler price target update

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.